BIBLIOGRAFIA
[1] W. Israel; Patologia Generale; Ed. Ambrosiana Milano; 25, 29; 363-370, 429-460
[2] Casarett, Doull's; Tossicologia; Emsi Roma; 8; 267-350 [3] Katzung; Farmacologia; 55; 934-937
[4] E. Schröder, C. Rufer, R. Schmiechen; Chimica Farmaceutica; Ed. SES Napoli; 2; 1101-1106, 1991
[5] www.findarticles.com
[6] Yingjie Zhang, Hao Fang, Jie Jiao, Wenfang Xu; The structure and function of Histone Deacetylases: the target for anti-cancer therapy; Current Medicinal Chemistry; 15 (27); 2840-2849; 2008
[7] Antonello Mai; The therapeutic uses of chromatin-modifying agents; Expert Opin. Ther. Targets, 11 (6); 835-851; 2007
[8] Paola Gallinari, Stefania Di Marco, Phillip Jones, Michele Pallaoro, Christian Steinkühler; HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics, Cell Research; 17; 195-211; 2007 [9] www.wikipedia.it
[10] Marielle Paris, Marina Porcelloni, Monica Binaschi, Daniela Fattori;
Hystone deacetylase inhibitors: from bench to clinic; J. Med. Chem.; 51 (6);
1505-1529; 2008
[11] C. M. Marson, P. Savy, A. S. Rioja, T. Mahadevan, C. Mikol, A. Veerupillai,
120
E. Nsubuga, A. Chahwan, S. P. Joel; Aromaticsulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxamides; J. Med.
Chem., 49, 800–805, 2006
[12] M. P. Glenn, P. Kahnberg, G. M. Boyle, K. A. Hansford, D. Hans, A. C.
Martyn, P. G. Parsons, D. P. Fairlie; Antiproliferative and phenotype- transforming antitumor agents derived from cysteine.; J. Med. Chem., 47, 2984–2994, 2004
[13] C. Shinji, T. Nakamura; S. Maeda, M. Yoshida, Y. Hashimoto, H.Miyachi;
Design and synthesis of phthalimide-type histonedeacetylase inhibitors; Bioorg.
Med. Chem. Lett., 7, 4427–4431, 2005
[14] W. Gu, I. Nusinzon, R. D. Smith, C. M. Horvath, R. B. Silverman;
Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid:
potent inhibition of histone deacetylases; Bioorg. Med. Chem.; 14; 3320–3329;
2006
[15] O. Moradei, S. Leit, N. Zhou, S. Fréchette, I. Paquin, S. Raeppel, F.
Gaudette, G. Bouchain, S. H. Woo, A. Vaisburg, M. Fournel, A. Kalita, A. Lu, M.
C. Trachy-Bourget, P. T. Yan, J. Liu, Z. Li, J. Rahil, V MacLeod, J. M. Besterman, D. Delorme; Substituted N-(2-amino-phenyl)-benzamides, (E)-N-(2- aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors; Bioorg. Med. Chem. Lett., 16, 4048–4052, 2006
[16] M. Duvic, J. Vu; Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma; Exp. Opin. Invest. Drugs; 16; 1111–
121
1120; 2007
[17] Nicolas Batty, Gabriel G. Malouf, Jean Pierre J. Issa; Histone deacetylase inhibitors as anti-neoplastic agents; Cancer Letters, doi:10.1016/
j.canlet.2009.03.013; 2009
[18] R. Piekarz, S. Bates; A review of depsipeptide and other histone deacetylase inhibitors in clinical trials; Curr. Pharm. Des.; 10; 2289–2298; 2004 [19] Oscar Moradei, Arkadii Vaisburg; Robert E. Martell; Hystone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide- type agents; Current Topics in Medicinal Chemistry; 8 (10); 841-858; 2008 [20] www.zolinza.com
122
